Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

BACKGROUND: β-Secretase enzyme (BACE) inhibition has been proposed as a priority treatment mechanism for Alzheimer’s disease (AD), but treatment initiation may need to be very early. We present proof of mechanism of atabecestat (also known as JNJ-54861911), an oral BACE inhibitor for the treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales: Timmers, Maarten, Streffer, Johannes Rolf, Russu, Alberto, Tominaga, Yushin, Shimizu, Hiroko, Shiraishi, Ayako, Tatikola, Kanaka, Smekens, Pascale, Börjesson-Hanson, Anne, Andreasen, Niels, Matias-Guiu, Jorge, Baquero, Miquel, Boada, Mercè, Tesseur, Ina, Tritsmans, Luc, Van Nueten, Luc, Engelborghs, Sebastiaan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106931/
https://www.ncbi.nlm.nih.gov/pubmed/30134967
http://dx.doi.org/10.1186/s13195-018-0415-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106931/
https://www.ncbi.nlm.nih.gov/pubmed/30134967
http://dx.doi.org/10.1186/s13195-018-0415-6

Ejemplares similares